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 2 
Abstract 22 
Background: Allergic diseases have seen a rise worldwide with children 23 
suffering the highest burden. Thus early prevention of allergic diseases is a 24 
public health priority.  25 
Objective: To synthesise the evidence from randomised controlled trials 26 
(RCTs) assessing the efficacy of vitamin interventions during pregnancy on 27 
developing allergic diseases in offspring.  28 
Methods: We searched CENTRAL, MEDLINE, SCOPUS, WHO’s Int. Clin. 29 
Trials Reg., E-theses and Web of Science. Study quality was evaluated using 30 
the Cochrane’s risk of bias tool. Included RCTs had a minimum of 1-month 31 
follow-up post gestation. 32 
Results: A total of five RCTs met the inclusion criteria, including 2456 33 
children that used vitamins C+E (one study), vitamin C (one study) and 34 
vitamin D (three studies) compared with placebo/control. Two studies were 35 
judged to have a high risk of bias for performance bias or high rate of loss to 36 
follow-up. All were rated as low risk of bias for blinding of outcome 37 
assessment. We did not perform meta-analysis with vitamin C or C+E studies 38 
due to high heterogeneity between the two included studies. However we did 39 
conduct a meta-analysis with trials on vitamin D (including 1493 children) and 40 
the results showed an association between prenatal intake of vitamin D and 41 
the risk of developing recurrent wheeze in offspring (RR=0.812, 95 % 42 
CI=0.67-0.98).  43 
Conclusion: The current evidence suggests that prenatal supplementation of 44 
vitamin D, might have a beneficial effect on recurrent wheezing in children. 45 
Longer-term follow-up of these studies are needed to ascertain whether this 46 
observed effect is a sustained. There is lack of evidence on the effect of other 47 
vitamins for prevention of respiratory and/or allergic outcomes.  48 
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List of abbreviations: 54 
WHO: World Health Organisation 55 
WHO’s Int. Clin. Trials. Reg.: World Health Organisation International 56 
Clinical Trials Registration 57 
RCT: Randomised Clinical Trial 58 
SPT: Skin Prick Test 59 
sIgE: specific Immunoglobulin E 60 
DARE: Database of Reviews of Effectiveness 61 
RR: Relative Risk or Risk Ratio 62 
CI: Confidence Interval 63 
ISI: Institute for Scientific Information 64 
 What is already known about this topic? 
Few observational studies suggest that vitamin deficiency is associated 
with developing higher prevalence of allergic diseases in children; 
however we need robust evidence from randomised controlled trials to 
determine if this is the case. 
 What does this article add to our knowledge? 
This systematic review indicates that prenatal intake of vitamin D may 
protect against development of recurrent childhood wheeze. As early 
childhood wheeze is not necessarily the same as asthma, longer-term 
follow-ups of these trials are required to establish the efficacy of vitamin 
D in prevention of actual asthma in later childhood.  
 How does this study impact current management guidelines? 
Consumption of higher doses of vitamin D during pregnancy needs to be 
considered in pregnancy management policies. However the effective 
dose could vary depending on the baseline level of vitamin-D in different 
regions. 
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Introduction 65 
In the last two decades allergic diseases have seen a rise worldwide with 66 
children suffering the highest burden of the condition1. Food allergies, eczema 67 
and asthma are the most common allergic disorders in children1-2. Due to the 68 
increasing burden of allergic diseases they are a key focus for public health. 69 
 70 
The Developmental Origins of Health and Diseases theory proposes that 71 
development is not dictated by a hard-wired genetic programme, instead the 72 
organism responds to the surrounding environment and the risk of many 73 
diseases is set during this time3. It has become increasingly evident that there 74 
is an important role for environmental factors in the onset of complex 75 
conditions such as allergic diseases and that the role of fixed genetic variation 76 
is far less than previously believed4. Therefore, new approaches towards 77 
disease prevention with an emphasis on early interventions i.e. pre-pregnancy 78 
and/or during pregnancy need to be widely investigated. Current evidence 79 
suggests that the role of maternal diet during pregnancy on subsequent 80 
disease development is a priority area for future studies5, as many of the 81 
immune modulatory processes may start in-utero. 82 
 83 
The role of environmental and life-style factors on developing allergies has 84 
been examined in a number of epidemiological studies. A systematic review 85 
has investigated the association of nutrient deficiencies on the risk of 86 
development of asthma and allergic diseases in children6. This review 87 
included 62 observational studies and indicated that vitamins A, D, and E; 88 
zinc; fruits and vegetables; and a Mediterranean diet during pregnancy may 89 
prevent asthma and wheeze. However, this review was based on 90 
observational studies which carry a high risk of bias and there is a need for 91 
secondary research based on summary of more robust interventional studies.  92 
 93 
The purpose of this systematic review is to summarise the existing 94 
randomised controlled trials evidence of the association between vitamin 95 
supplements during pregnancy and the risk of developing allergic disorders in 96 
the offspring.  97 
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Methods 98 
Criteria for considering studies for this review 99 
Types of studies 100 
Only randomised controlled trials (RCT) (including cluster randomised 101 
controlled trials and quasi-randomised controlled trials) with a minimum 102 
follow-up of one month postnatally were included. The review considered 103 
studies which documented clinical outcome data and used any types of 104 
vitamins. No language restriction was applied.  105 
Types of participants 106 
Pregnant women and their offspring, regardless of their location were 107 
considered as the target group for this systematic review. High risk 108 
populations were not excluded. 109 
Types of interventions 110 
Studies that used any vitamin supplementation during pregnancy, irrespective 111 
of dose, formulation or mode of delivery and composition e.g. oil, tablet.    112 
Trials were also included if the intervention(s) had been extended after 113 
pregnancy either during breast-feeding or with the infants or both.  114 
Outcomes of interest 115 
Trials were included if they had reported clinical outcomes of allergy in the 116 
offspring, either as a primary or secondary endpoint. Allergic outcomes were 117 
defined as: asthma, wheeze, rhinitis, eczema, food allergy and positive skin 118 
prick test (to any allergen) and elevated specific IgE. Outcomes included were 119 
those, which had utilised a validated method as opposed to parental reports. 120 
Search strategy for identification of studies 121 
A comprehensive search strategy, including all the relevant synonyms for the 122 
main concepts, was developed covering the main bibliographic databases 123 
(online repository). Trials were identified through systematic searches within 124 
three main electronic databases, as advised by the Cochrane collaboration7: 125 
a. Cochrane Library (current issue) including: 126 
 Cochrane Database of Systematic Reviews (CDSR)  127 
 CENTRAL (trials) 128 
 DARE 129 
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b. MEDLINE (EBSCOhost)  130 
c. SCOPUS 131 
When searching MEDLINE, the subject-specific terms were combined with the 132 
Cochrane Highly Sensitive Search Strategy for identifying randomised trials in 133 
MEDLINE: sensitivity-maximising version7. We adapted the preliminary 134 
search strategy for MEDLINE (EBSCOhost) for use in the other databases 135 
when relevant. The last search for literature was conducted in January 2016.  136 
The clinical trials registry and WHO platform were searched for ongoing and 137 
recently completed trials. Conference proceedings were identified through the 138 
ISI Web of Science and, for retrieving theses the British Library E-Theses 139 
Online Service was searched. No language or publication status restrictions 140 
were imposed. References of included studies were crosschecked for 141 
additional studies.   142 
Data collection and analysis 143 
Selection of studies 144 
The main reviewer (MV) screened all the search results against the eligibility 145 
criteria and all those which were clearly irrelevant were excluded from further 146 
consideration. Thereafter, a tailored eligibility form was used by MV to 147 
appraise the retrieved studies, abstract and full text for relevance against the 148 
full inclusion criteria. Where there was uncertainty about inclusion of a 149 
particular study, other members of the review team (HM & TD) were consulted 150 
and a consensus was reached about the study eligibility. All the included 151 
studies were discussed and approved by the review team.  152 
Data extraction 153 
MV extracted the data using a tailored data extraction form (online repository). 154 
Detailed information on study characteristics were recorded. Throughout the 155 
data extraction process, any disagreements about the interventions and 156 
outcomes were discussed and resolved within the review team. There was no 157 
blinding to the name of authors, institutions, journals or the outcomes of the 158 
trials during the process. Ten percent of all the extracted data was randomly 159 
selected and double checked by a second reviewer (HM) for accuracy against 160 
the trial reports. 161 
 7 
Assessment of risk of bias in included studies 162 
The risk of bias tool described in the Cochrane Handbook for Systematic 163 
Reviews for Interventions was used to appraise the studies8. The tool includes 164 
seven domains: random sequence generation, allocation concealment, 165 
blinding of participants and personnel, blinding of outcome assessments, 166 
incomplete outcome data, selective outcome reporting and other bias.  167 
Measurement of treatment effect 168 
Dichotomous data was analysed as risk ratios or relative risk (RR) with 95% 169 
CI and continuous data as mean difference or standardised mean difference, 170 
with 95% CI.  171 
Unit of analysis issues 172 
In trials with more than one intervention arm, multiple pairwise comparisons of 173 
intervention groups versus comparator were avoided. Therefore, data from 174 
different intervention arms were pooled for an overall comparison with the 175 
control or placebo arm. The weight assigned to the control group was 176 
considered as the total number of participants in the comparator group versus 177 
the total number of participants in the combined intervention arms9.  178 
Handling missing data 179 
All the relevant reported information for the number of missing participants 180 
was extracted and if undocumented, this was incorporated into the 181 
assessment of risk of bias. No imputed techniques were used for retrieving 182 
missing data.  183 
Assessment of heterogeneity 184 
We used visual inspection of forest plots and also, the Chi2 test to measure 185 
statistical heterogeneity between effect sizes of included studies (P<0.05)10. I2 186 
statistics were used to quantify the amount of possible variability in effect 187 
estimates that is due to heterogeneity rather than chance (I2 30 moderate 188 
heterogeneity, I2 ≥75 considerable heterogeneity).  189 
Assessment of reporting biases 190 
Every effort was made to identify unpublished studies through searching 191 
abstracts and ongoing trials databases. Publication bias was assessed using 192 
funnel plots11. The asymmetry was assessed visually in the plots and no 193 
formal statistical tests were conducted. The funnel plot was helpful to explore 194 
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possible small study biases for some of the primary outcomes (online 195 
repository).  196 
Data synthesis  197 
We used Eppi Reviewer version 4.4.3.0. for conducting meta-analyses using 198 
random-effects model. Dichotomous data were entered as events and the 199 
number of participants. Data were pooled using random-effects model where 200 
heterogeneity was reported as ≤75%7. We also reported relative risk as a 201 
statistical choice in conducting the meta-analyses, as it is easy to interpret12. 202 
Studies were grouped under one umbrella as “any vitamins” for performing 203 
meta-analyses. 204 
Subgroup analysis and investigation of heterogeneity  205 
We performed sub-group analyses based on the type of vitamin and type of 206 
the control group (i.e. placebo versus no treatment).  207 
Sensitivity analysis 208 
We did not conduct any sensitivity analysis because of the small number of 209 
studies that contributed to meta-analyses.  210 
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Results  211 
The results of the search strategy yielded 341 studies, of which 26 were 212 
selected for full-text assessment (Figure1). We included 5 RCTs comparing at 213 
least one vitamin with a control that met the inclusion criteria for this 214 
systematic review.  215 
 216 
These included trials (including total of 2456 children) were represented by 217 
five original papers13-17 and four grouped as their companion papers18-21. 218 
Table 1 shows the characteristics of the included trials, their companion 219 
papers and study population. The trials were conducted in United Kingdom, 220 
Denmark and United States. The types of vitamin supplementations included 221 
were as vitamins C+E13, vitamin D14,16-17 and crushed vitamin C15. The 222 
duration of intervention and follow-up in the included studies varied from 3.5-4 223 
to 7.5 months and 12 to 36 months respectively. In trials that used vitamins C 224 
and C+E, a higher blood concentration of vitamins was observed in those 225 
assigned antioxidants13&15. In trials that used vitamin D, level of maternal 25-226 
hydroxyvitamin D measured either at third trimester or after delivery and was 227 
significantly higher in the treatment versus comparison group14, 16&17. The 228 
most frequently reported outcomes were wheeze and eczema. As expected 229 
with systematic reviews there were differences between the included trials in 230 
terms of type of the population, supplementation used and the comparators. 231 
We have therefore described the results of individual studies narratively and 232 
only conducted meta-analysis when there was no evidence of statistical 233 
heterogeneity. The definition and diagnosis method of the outcomes in each 234 
study are presented in online repository. 235 
 236 
Vitamin C studies 237 
Greenough et al. (2010)13 study 238 
The study was conducted in the U.K between August 2003 to June 2007. The 239 
studied sample were pregnant women at risk of developing pre-eclampsia. 240 
Women were supplemented with daily vitamins C (1,000mg) tablets and E 241 
(400IU) gelatin capsules, from 16-22 gestation weeks until delivery. Women in 242 
the control group received identical tablets of microcrystalline cellulose with 243 
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addition of tartaric acid and citric acid along gelatin capsules of sunflower 244 
seed oil. Compliance with the intervention was measured by counts of 245 
returned pills. Primarily this study was designed to prevent the risk of fetal 246 
growth restriction and premature delivery in the women18 and the extended 247 
follow-up at 2 years has assessed the efficiency of the vitamin intervention on 248 
respiratory outcomes in children.  249 
 250 
The list of the reported outcomes in the study is shown in Table 1. The 251 
outcomes of “asthma” and “eczema” are reported at 1-year age and “recurrent 252 
wheeze” at 2 years. No statistically significant association was observed 253 
between the intervention and control group for prevention of recurrent wheeze 254 
(10/386 vs. 11/366, OR=0.83, 95% CI=0.26-2.59, p=0.66) and asthma 255 
(23/386 vs. 23/366, OR=0.94, 95% CI=0.42-2.11, p=0.85). Additionally the 256 
results did not show a significant association between prenatal intake of 257 
vitamin C+E and prevention of eczema (98/386 vs. 86/366, OR=1.10, 95% 258 
CI=0.70-1.74, p=0.58). 259 
 260 
McEvoy et al. (2014)15 study 261 
The study was conducted in U.S.A between March 2007 and January 2011. 262 
The studied sample were smoking pregnant women. Women were 263 
supplemented with daily crushed vitamin C (500mg) gel capsules, from 22nd 264 
gestation weeks until delivery. Women in the control group received ground 265 
cornstarch in gel capsules. Adherence was measured by dividing the number 266 
of capsules taken by the total number prescribed in a given period.    267 
 268 
The study reported the efficiency of consumption of vitamin C during 269 
pregnancy on pulmonary function tests and wheezing in children at 1-year 270 
age. The list of the reported outcomes in the study is shown in Table 1. The 271 
results of the unadjusted analysis showed no significant statistical association 272 
between the intervention and control groups for outcome measure defined as 273 
“recurrent wheeze” (9/76 vs. 17/83, RR=0.56, 95% CI=0.27-1.18, p=0.13). A 274 
significant difference was observed for the outcome of “at least 1 episode of 275 
wheezing” between the intervention and control groups (15/76 vs. 31/83, 276 
RR=0.56, 95% CI=0.33-0.95, p=0.03). 277 
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Given the fact that there is high heterogeneity between the studies that 278 
supplemented pregnant women prenatally with vitamin C, we did not perform 279 
meta-analysis for these trials.  280 
 281 
Vitamin D studies  282 
Goldring et al. (2013)14 study 283 
The study was conducted in the U.K between April and November 2007. This 284 
study recruited pregnant women with multiple ethnicities. The study 285 
introduced two intervention arms, as women were randomised either to 286 
receive a daily dose of ergocalciferol (800IU) or a single oral dose of 287 
cholecalciferol (200,000IU, bolus), from 27 gestation weeks until delivery. The 288 
comparator in this study was defined as “no treatment”. Adherence was 289 
measured by telephone calls during pregnancy.  290 
 291 
This study followed up children to up 3 years of age and this systematic 292 
review only reports the results for the intervention arm of daily vitamin D. The 293 
results of unadjusted analysis for “recurrent wheezing” showed no statistical 294 
significant association between prenatal intake of daily vitamin D and control 295 
group (8/56 vs. 7/50, RR=1.02, 95% CI=0.40-2.61, p=0.97). Furthermore, no 296 
significant association was observed for the outcome measure of “wheeze 297 
with positive asthma predictive index” (6/56 vs. 7/50, RR=0.77, 95% CI=0.28-298 
2.13, p=0.61) between the study arms. The outcomes of “eczema in the last 299 
year” (11/55 vs. 7/49, RR=1.40, 95% CI=0.59-3.33, p=0.44) and “food allergy 300 
diagnosis” (8/55 vs. 3/49, RR=2.38, 95% CI=0.67-8.46, p=0.16) did not show 301 
a significant statistical association for the prenatal consumption of daily 302 
vitamin D in comparison to control.  303 
 304 
Chawes et al. (2016)16 study 305 
The study was conducted in Denmark between 2008 to 2010. The studied 306 
sample were unselected pregnant women. Women were supplemented with 307 
daily vitamin D3 (2,400IU) tablets, from 24 gestation weeks to one week after 308 
delivery. Women in the control arm received tablets containing no active 309 
substance. In addition, women assigned to both intervention and control arms 310 
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received an extra 400IU dose of vitamin D3, as part of their routine care. 311 
Compliance to the intervention was measured by counts of returned pills.  312 
 313 
The study reported cumulative incidence of the allergic outcomes by 3 years 314 
of age. The results of unadjusted analysis indicated that the risk of developing 315 
recurrent wheeze did not show a significant difference between the 316 
intervention and control group (47/295 vs. 57/286, HR=0.76, 95% CI=0.52-317 
1.12, p=0.16). Asthma was reported at 3 years of age only and no significant 318 
difference was observed between the intervention and control groups (32/278 319 
vs. 47/271, OR=0.82, 95% CI=0.50-1.36, p=0.45). Furthermore there was not 320 
a significant statistical difference between the study arms for eczema as an 321 
outcome (68/295 vs. 72/286, HR=0.90, 95% CI=0.65-1.26, p=0.55). Children 322 
in the intervention arm reported statistically significant “lower episodes of 323 
troublesome lung symptoms” compared to the control group (5.9 vs. 7.2, 324 
IRR=0.83, 95% CI=0.71-0.97, p=0.02). The cumulative results for SPT and 325 
sIgE outcomes were not statistically different between the intervention and 326 
control group (24/294 vs. 19/283, OR=1.24, 95% CI=0.66-2.31, p=0.51) and 327 
(34/289 vs. 22/278, OR=1.55, 95% CI=0.89-2.73, p=0.13) respectively.  328 
 329 
Litonjua et al. (2016)17 study 330 
The study was conducted in U.S.A between 2009 to 2011. The study sample 331 
were women with a history of atopy. Women were supplemented with daily 332 
vitamin D3 (4,000IU) tablets, between 10-18 gestation weeks until delivery. 333 
The nature of the placebo capsules was not reported. Women in both study 334 
arms also received a multivitamin with 400IU of vitamin D. Adherence to the 335 
intervention was measured by electronic medication container caps. 336 
 337 
The study reported cumulative incidence of the allergic outcomes by 3 years 338 
of age. The outcomes of “asthma or recurrent wheeze” were reported together 339 
and the results showed no significant statistical difference between the 340 
intervention and control groups (98/405 vs. 120/401, HR=0.8, 95% CI=0.6-341 
1.0, p=0.051). There was also no significant statistical difference in the risk of 342 
developing “eczema with rash” in the study arms (83/405 vs. 89/401, HR=0.9, 343 
95% CI=0.7-1.2, p=0.56). The result for positive sIgE tests at 3 years showed 344 
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a significant statistical difference between the intervention and control group 345 
(43/405 vs. 50/401, MD=-1.7, 95% CI=-3.4-0.0, p=0.02). 346 
 347 
Meta-analyses of vitamin D studies 348 
We conducted a meta-analysis for the outcome measure of “recurrent 349 
wheeze” for trials that used vitamin D prenatally in pregnant women. Figure 2 350 
shows the Forest plot for this outcome. Three trials contributed to the meta-351 
analysis including a total of 1,493 children. No statistical heterogeneity was 352 
observed between the included trials (Chi2=0.16, p=0.92, I2=0%) (Figure 2). 353 
The results of the present meta-analysis showed an association between 354 
maternal intake of daily vitamin D during pregnancy and a lower risk of 355 
developing recurrent wheeze in offspring (RR=0.812, 95% CI=0.673-0.98). 356 
We also conducted the meta-analysis including only the two recent vitamin D 357 
trials16&17 and it yielded similar results (Forest plot not shown). 358 
 359 
Risk of bias in included trials 360 
The risk of bias figures and authors’ judgments are presented in online 361 
repository. Only one trial was deemed to have low risk of bias across all 362 
domains17. Of the 5 trials, most had adequate random sequence generation 363 
(n=3), allocation concealment (n=3) and performance bias (n=3). All trials 364 
were rated as having a low risk of bias for blinding of outcome assessment 365 
and selective outcome reporting. Completeness of outcome data was rated as 366 
having high risk of bias for one trial13 since the study had a high loss to follow-367 
up and the authors acknowledged the fact that the study was an unplanned 368 
extended follow-up of the original trial for measuring allergic outcomes in 369 
children. The original trial was primarily designed to assess the efficacy of 370 
vitamins C and E supplementation on developing pre-eclampsia in women at 371 
increased risk.  372 
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Discussion 373 
This is the first systematic review of randomised controlled trials that 374 
investigated the association of prenatal intake of vitamins on the risk of 375 
developing allergic/respiratory diseases in the offspring. We identified five 376 
RCTs with a total of 2456 children. The studies were of unselected pregnant 377 
women16, women with a history of atopy17, pregnant women at risk of 378 
developing pre-eclampsia13, different ethnic/race groups14 and smoking 379 
pregnant women15. Two studies were judged to have a high risk of bias due to 380 
their performance bias13-14 or high rate of loss to follow-up13. All trials were 381 
rated having low risk of bias for blinding of outcome assessment. It was not 382 
possible to conduct meta-analyses for vitamin C studies due to observed 383 
differences between the included trials. Maternal vitamin D consumption 384 
during pregnancy was associated with a lower risk of developing recurrent 385 
wheeze in offspring, when compared to placebo/control. However we were 386 
not able to investigate the efficiency of vitamin D on other allergic outcomes 387 
since outcomes were reported differently in the included trials. In all trials, 388 
supplementation with vitamins significantly increased the concentration of 389 
vitamins in the intervention group compared to the control group by the end of 390 
the intervention.  391 
 392 
Observational studies typically report a beneficial effect of higher intake of 393 
vitamin D as well as antioxidants during pregnancy on allergic outcomes22-23. 394 
The results from this systematic review proposed a protective effect of 395 
prenatal intake of vitamin D during pregnancy for prevention of recurrent 396 
wheeze in offspring. However we could not address the effect of prenatal 397 
intake of vitamin C or D on other allergic outcomes owing to the observed 398 
heterogeneity between the trials.  399 
 400 
It is possible that the follow-up periods of the studies for this review have been 401 
too short to detect other allergic outcomes i.e. asthma. For example, 402 
wheezing is known as a primary symptom of asthma in early childhood25 and 403 
about 40% of childhood wheeze will persist later in life and will eventually 404 
develop into asthma by 6 years of age26, indicating majority of wheeze during 405 
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infancy are in fact acute respiratory infection. Therefore, extended follow-up of 406 
these trials could help to provide a clearer answer as to whether the vitamin D 407 
intervention is beneficial for asthma prevention. 408 
  409 
There were also some limitations in the studies’ design. For example, the 410 
trials were statistically underpowered to detect an effect for their primary 411 
and/or secondary outcome measures. Significant differences were only 412 
observed for some of the secondary outcomes as “at least 1 episode of 413 
wheezing”14, “episodes of troublesome lung symptoms”16 and “positive sIgE”17 414 
and trials failed to show a beneficial effect for primary allergic outcomes such 415 
as wheeze and asthma in children. Also, the trials used different doses of 416 
vitamins during pregnancy. The dose of vitamin D varied between 800-4000IU 417 
and doses of vitamin C and/or E, varied between 500-1000mg. It is possible 418 
to hypothesis that lower doses of vitamins may have failed to reach the 419 
desirable level of 25-hydroxyvitamin D or antioxidants in pregnant women to 420 
have an influential effect on the fetal immune programming and lung 421 
function27-29. However this is refuted by studies which have reported similar 422 
effect size using higher doses of vitamin D16&17. A previous RCT by 423 
addressing the safety and efficacy of vitamin D supplementation during 424 
pregnancy showed that a 4000IU vitamin D is a safe approach and was 425 
necessary to optimise the circulating concentration of 25-hydroxyvitamin D 426 
levels to ≥ 80nmol/L30. There is limited evidence on the safety of vitamins C 427 
and E intake at any stage of pregnancy; however the Institute of Medicine’s 428 
Food and Nutrition Board have set an upper limit of 2000mg and 1000mg per 429 
day for vitamins C and E ingestion respectively during pregnancy in the 430 
United States31.  431 
 432 
Further, in all trials the intervention was started in the 2nd trimester in 433 
pregnancy. However the development of the lungs begins in the first trimester 434 
in pregnancy and vitamin D plays an immunomodulatory role in the 435 
development of lung and immune system32. Therefore the interventions might 436 
have commenced too late in pregnancy or some used too low dose of vitamin 437 
D to have a beneficial impact on lung development. Finally, the studies 438 
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recruited different types of population, which limits the generalisability of the 439 
studies. Baseline levels of vitamin D vary in different geographical areas33 and 440 
this issue has not been addressed in the conducted trials. Well-designed trials 441 
are necessary to address all these possible confounders among different 442 
populations34. Further larger scale research should administer vitamin D 443 
earlier in pregnancy or pre-pregnancy and employs appropriate doses of 444 
vitamin D to achieve a desirable level of vitamin D in maternal and fetal blood. 445 
Furthermore, studies assessing the efficiency of nutrients are required to 446 
consider the defined guidelines in their clinical design enabling to test the 447 
associated hypothesis in a valid manner35.    448 
 449 
To date, no other systematic review has evaluated the efficacy of prenatal 450 
vitamins on the prevention of allergic and/or respiratory outcomes in children. 451 
The result from the current evidence is promising that prenatal intake of 452 
vitamin D could protect childhood wheeze. The role of maternal consumption 453 
of vitamins during pregnancy on the risk of developing other allergic outcomes 454 
and sensitisation needs to be investigated in larger well-designed trials. 455 
Further it will be important for future research to examine the impact of the 456 
timing of the intervention and the optimum dose of vitamins. We were unable 457 
to perform any meta-analyses on the timing or dose of intervention and study 458 
populations due to the small number of trials that could contribute to meta-459 
analyses.  460 
 461 
The current evidence suggests that prenatal intake of daily vitamin D might 462 
protect against recurrent childhood wheeze; however there is currently lack of 463 
evidence that prenatal intake of vitamins can prevent any other 464 
allergic/respiratory outcomes. 465 
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Figure legends  
 
Figure 1: Study flow diagram, following PRISMA criteria 
 
Figure 2: Forest plot for daily vitamin D intake vs. placebo or no 
treatment as the control for prevention of recurrent wheeze in offspring 
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Table 1. Characteristics of included trials and study population for Vitamins and prevention of respiratory and/or allergic outcomes in 
offspring 
Primary 
article  
Companion 
articles 
Country, 
enrolment 
period 
No. of 
participa
nts** 
Age 
at last  
F-U 
Sample: 
high risk 
of Atopy 
Intake of 
intervention  
From/until 
Duration of 
intervention 
(months)
*
 
Vitamin 
product 
Placebo 
 
Total daily 
dose 
Outcomes 
reported 
 
Greenough 
2010
13
 
Poston 
2006 
U.K. 
2003-05 
2404 
mothers 
2yrs. No From the 
2nd 
trimester 
of 
pregnancy 
to delivery 
6-6.5  Vitamin 
C & E 
Microcrystalline 
cellulose with 
addition of 
tartaric & 
citric acid + 
sunflower 
seed oil 
1000mg Vit 
C & 400 IU 
RRR  
a-tocopherol, 
daily 
-Wheeze 
-Eczema 
-Asthma 
-Cough 
-Breathing 
difficulty 
Goldring 
2013
14
 
Yu 2009 U.K. 
2007-not 
mentioned 
180 
mothers 
3yrs. No 27wks to 
delivery 
3months + 
1week 
Vitamin 
D 
(cholecalc
iferol) or 
Vitamin 
D 
(ergocalci
ferol) 
No treatment Single oral 
dose of 
200,000 IU 
(bolus) 
or 
800 IU 
daily  
-Wheeze 
-Eczema 
-Food allergy 
-Rhinitis 
-Atopy 
-URTI# 
-LRTI## 
-Inhaled 
bronchodilator 
or steroid 
McEvoy 
2014
15
 
McEvoy 
2013 
(conferen
ce 
abstract) 
U.S.A  
2007-11 
179 
mothers 
1yr No 22wks to 
delivery 
4-4.5 Crushed 
vitamin 
C 
Ground 
cornstarch 
500 mg, 
daily 
-Wheeze 
-Breathing 
difficulty 
Chawes 
2016
16
 
Bisgaard 
2013 
Denmark 
2008-2010 
623 3yrs No 24wks to 
1w after 
delivery 
3.5-4 + 
1week 
Vitamin 
D3 
(cholecalc
iferol) 
Tablets 
containing no 
active 
substance 
2400 IU, 
once a day 
-Persistent 
wheeze 
-Asthma 
-URTI# 
-LRTI## 
-Episodes of 
lung symptoms 
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-SPT 
-sIgE 
Litonjua 
2016
17
 
Litonjua 
2014 
USA  
2009-2011 
880 3yrs Yes Between 
10-18wks 
to delivery 
5-7.5 Vitamin 
D & 
placebo  
Not 
mentioned 
4000 IU, 
daily 
-Wheeze or 
asthma 
-Eczema with 
rash 
-LRTI## 
-Total IgE 
(mean) 
-Sensitisation 
(aeroallergens) 
-sIgE 
#URTI=Upper Respiratory Tract Infection        ##LRTI=Lower Respiratory Tract Infection 
 
